Which has higher valuation & earnings, FTH or IPHA?

Sensei Biotherapeutics has higher earnings, but lower revenue than Innate Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sensei Biotherapeutics N/A N/A -$21.08M -$141.65 N/A Innate Pharma $10.19M 16.12 -$55.64M N/A N/A

Is FTH or IPHA more profitable?

Innate Pharma's return on equity of 0.00% beat Sensei Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Sensei Biotherapeutics N/A -1,012.17% -175.69% Innate Pharma N/A N/A N/A

Which has better valuation & earnings, NVCT or IPHA?

Nuvectis Pharma has higher earnings, but lower revenue than Innate Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuvectis Pharma N/A N/A -$26.44M -$1.31 N/A Innate Pharma $10.19M 16.12 -$55.64M N/A N/A

Is NVCT or IPHA more profitable?

Innate Pharma's return on equity of 0.00% beat Nuvectis Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Nuvectis Pharma N/A -184.25% -105.24% Innate Pharma N/A N/A N/A

Which has higher valuation & earnings, PHAR or IPHA?

Pharming Group has higher revenue and earnings than Innate Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pharming Group $376.13M 1.78 $2.85M $0.12 78.67 Innate Pharma $10.19M 16.12 -$55.64M N/A N/A

Which has preferable earnings & valuation, MDXG or IPHA?

MiMedx Group has higher revenue and earnings than Innate Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MiMedx Group $418.63M 1.63 $48.58M $0.04 117.25 Innate Pharma $10.19M 16.12 -$55.64M N/A N/A

Which has better valuation and earnings, IPHA or DBVT?

Innate Pharma has higher revenue and earnings than DBV Technologies. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Innate Pharma $10.19M 16.12 -$55.64M N/A N/A DBV Technologies $5.64M 100.67 -$146.95M -$3.51 N/A

Innate Pharma (IPHA) Competitors

$1.46 -0.01 (-0.41%)

As of 09:50 AM Eastern

Compare

IPHA vs. FTH, NVCT, PHAR, MDXG, and DBVT

Should you buy Innate Pharma stock or one of its competitors? Innate Pharma's main competitors and comparable companies include Sensei Biotherapeutics (FTH), Nuvectis Pharma (NVCT), Pharming Group (PHAR), MiMedx Group (MDXG), and DBV Technologies (DBVT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Innate Pharma compare to Sensei Biotherapeutics?

Sensei Biotherapeutics (NASDAQ:FTH) and Innate Pharma (NASDAQ:IPHA) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership.

Sensei Biotherapeutics has a beta of -0.29, indicating that its share price is 129% less volatile than the broader market. Comparatively, Innate Pharma has a beta of 0.72, indicating that its share price is 28% less volatile than the broader market.

In the previous week, Sensei Biotherapeutics had 4 more articles in the media than Innate Pharma. MarketBeat recorded 5 mentions for Sensei Biotherapeutics and 1 mentions for Innate Pharma. Innate Pharma's average media sentiment score of 1.41 beat Sensei Biotherapeutics' score of 0.11 indicating that Innate Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Sensei Biotherapeutics	Neutral
Innate Pharma	Positive

10.5% of Sensei Biotherapeutics shares are held by institutional investors. Comparatively, 0.2% of Innate Pharma shares are held by institutional investors. 7.0% of Sensei Biotherapeutics shares are held by insiders. Comparatively, 31.9% of Innate Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Sensei Biotherapeutics presently has a consensus target price of $56.25, indicating a potential upside of 161.51%. Innate Pharma has a consensus target price of $6.67, indicating a potential upside of 353.51%. Given Innate Pharma's higher possible upside, analysts clearly believe Innate Pharma is more favorable than Sensei Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sensei Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93
Innate Pharma	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Sensei Biotherapeutics has higher earnings, but lower revenue than Innate Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$141.65	N/A
Innate Pharma	$10.19M	16.12	-$55.64M	N/A	N/A

Innate Pharma's return on equity of 0.00% beat Sensei Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sensei Biotherapeutics	N/A	-1,012.17%	-175.69%
Innate Pharma	N/A	N/A	N/A

Summary

Innate Pharma beats Sensei Biotherapeutics on 7 of the 13 factors compared between the two stocks.

How does Innate Pharma compare to Nuvectis Pharma?

Nuvectis Pharma (NASDAQ:NVCT) and Innate Pharma (NASDAQ:IPHA) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

In the previous week, Nuvectis Pharma had 3 more articles in the media than Innate Pharma. MarketBeat recorded 4 mentions for Nuvectis Pharma and 1 mentions for Innate Pharma. Innate Pharma's average media sentiment score of 1.41 beat Nuvectis Pharma's score of 0.98 indicating that Innate Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Nuvectis Pharma	Positive
Innate Pharma	Positive

Nuvectis Pharma has a beta of -0.24, suggesting that its stock price is 124% less volatile than the broader market. Comparatively, Innate Pharma has a beta of 0.72, suggesting that its stock price is 28% less volatile than the broader market.

Nuvectis Pharma has higher earnings, but lower revenue than Innate Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A
Innate Pharma	$10.19M	16.12	-$55.64M	N/A	N/A

Innate Pharma's return on equity of 0.00% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvectis Pharma	N/A	-184.25%	-105.24%
Innate Pharma	N/A	N/A	N/A

Nuvectis Pharma presently has a consensus price target of $36.25, suggesting a potential upside of 99.72%. Innate Pharma has a consensus price target of $6.67, suggesting a potential upside of 353.51%. Given Innate Pharma's higher possible upside, analysts clearly believe Innate Pharma is more favorable than Nuvectis Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Innate Pharma	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

96.8% of Nuvectis Pharma shares are owned by institutional investors. Comparatively, 0.2% of Innate Pharma shares are owned by institutional investors. 28.6% of Nuvectis Pharma shares are owned by insiders. Comparatively, 31.9% of Innate Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Innate Pharma beats Nuvectis Pharma on 8 of the 13 factors compared between the two stocks.

How does Innate Pharma compare to Pharming Group?

Pharming Group (NASDAQ:PHAR) and Innate Pharma (NASDAQ:IPHA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations.

Pharming Group has a beta of -0.05, suggesting that its stock price is 105% less volatile than the broader market. Comparatively, Innate Pharma has a beta of 0.72, suggesting that its stock price is 28% less volatile than the broader market.

In the previous week, Pharming Group had 3 more articles in the media than Innate Pharma. MarketBeat recorded 4 mentions for Pharming Group and 1 mentions for Innate Pharma. Innate Pharma's average media sentiment score of 1.41 beat Pharming Group's score of 0.42 indicating that Innate Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Pharming Group	Neutral
Innate Pharma	Positive

Pharming Group has higher revenue and earnings than Innate Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharming Group	$376.13M	1.78	$2.85M	$0.12	78.67
Innate Pharma	$10.19M	16.12	-$55.64M	N/A	N/A

Pharming Group has a net margin of 2.51% compared to Innate Pharma's net margin of 0.00%. Pharming Group's return on equity of 3.40% beat Innate Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharming Group	2.51%	3.40%	1.90%
Innate Pharma	N/A	N/A	N/A

0.0% of Pharming Group shares are owned by institutional investors. Comparatively, 0.2% of Innate Pharma shares are owned by institutional investors. 2.1% of Pharming Group shares are owned by company insiders. Comparatively, 31.9% of Innate Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Pharming Group presently has a consensus price target of $38.67, indicating a potential upside of 309.60%. Innate Pharma has a consensus price target of $6.67, indicating a potential upside of 353.51%. Given Innate Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Innate Pharma is more favorable than Pharming Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharming Group	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Innate Pharma	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Innate Pharma beats Pharming Group on 8 of the 14 factors compared between the two stocks.

How does Innate Pharma compare to MiMedx Group?

MiMedx Group (NASDAQ:MDXG) and Innate Pharma (NASDAQ:IPHA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability and risk.

In the previous week, MiMedx Group and MiMedx Group both had 1 articles in the media. Innate Pharma's average media sentiment score of 1.41 beat MiMedx Group's score of 0.94 indicating that Innate Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
MiMedx Group	Positive
Innate Pharma	Positive

79.2% of MiMedx Group shares are held by institutional investors. Comparatively, 0.2% of Innate Pharma shares are held by institutional investors. 2.5% of MiMedx Group shares are held by company insiders. Comparatively, 31.9% of Innate Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

MiMedx Group has higher revenue and earnings than Innate Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiMedx Group	$418.63M	1.63	$48.58M	$0.04	117.25
Innate Pharma	$10.19M	16.12	-$55.64M	N/A	N/A

MiMedx Group has a beta of 1.18, indicating that its stock price is 18% more volatile than the broader market. Comparatively, Innate Pharma has a beta of 0.72, indicating that its stock price is 28% less volatile than the broader market.

MiMedx Group presently has a consensus target price of $8.57, indicating a potential upside of 82.76%. Innate Pharma has a consensus target price of $6.67, indicating a potential upside of 353.51%. Given Innate Pharma's higher probable upside, analysts clearly believe Innate Pharma is more favorable than MiMedx Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Innate Pharma	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

MiMedx Group has a net margin of 1.76% compared to Innate Pharma's net margin of 0.00%. MiMedx Group's return on equity of 12.09% beat Innate Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiMedx Group	1.76%	12.09%	9.22%
Innate Pharma	N/A	N/A	N/A

Summary

MiMedx Group beats Innate Pharma on 9 of the 13 factors compared between the two stocks.

How does Innate Pharma compare to DBV Technologies?

Innate Pharma (NASDAQ:IPHA) and DBV Technologies (NASDAQ:DBVT) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

In the previous week, DBV Technologies had 2 more articles in the media than Innate Pharma. MarketBeat recorded 3 mentions for DBV Technologies and 1 mentions for Innate Pharma. Innate Pharma's average media sentiment score of 1.41 beat DBV Technologies' score of 0.04 indicating that Innate Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Innate Pharma	Positive
DBV Technologies	Neutral

Innate Pharma presently has a consensus target price of $6.67, indicating a potential upside of 353.51%. DBV Technologies has a consensus target price of $48.50, indicating a potential upside of 437.10%. Given DBV Technologies' higher possible upside, analysts plainly believe DBV Technologies is more favorable than Innate Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innate Pharma	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
DBV Technologies	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

0.2% of Innate Pharma shares are owned by institutional investors. Comparatively, 71.7% of DBV Technologies shares are owned by institutional investors. 31.9% of Innate Pharma shares are owned by insiders. Comparatively, 1.1% of DBV Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Innate Pharma has higher revenue and earnings than DBV Technologies.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innate Pharma	$10.19M	16.12	-$55.64M	N/A	N/A
DBV Technologies	$5.64M	100.67	-$146.95M	-$3.51	N/A

Innate Pharma has a beta of 0.72, suggesting that its share price is 28% less volatile than the broader market. Comparatively, DBV Technologies has a beta of -1.04, suggesting that its share price is 204% less volatile than the broader market.

Innate Pharma has a net margin of 0.00% compared to DBV Technologies' net margin of -3,506.53%. Innate Pharma's return on equity of 0.00% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innate Pharma	N/A	N/A	N/A
DBV Technologies	-3,506.53%	-119.33%	-84.43%

Summary

Innate Pharma beats DBV Technologies on 8 of the 12 factors compared between the two stocks.

Get Innate Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IPHA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IPHA vs. The Competition

Export

Metric	Innate Pharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$163.56M	$3.93B	$7.26B	$13.21B
Dividend Yield	N/A	3.65%	2.52%	22.89%
P/E Ratio	N/A	11.31	206.66	19.94
Price / Sales	16.05	1,148.46	562.21	81.34
Price / Cash	N/A	118.50	77.16	53.04
Price / Book	-5.63	17.08	10.75	6.03
Net Income	-$55.64M	-$22.69M	$3.50B	$380.34M
7 Day Performance	-3.68%	-4.43%	-2.91%	-2.34%
1 Month Performance	-20.86%	-12.48%	-7.38%	-5.31%
1 Year Performance	-27.88%	7.60%	2.96%	-2.94%

Innate Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IPHA Innate Pharma	3.4873 of 5 stars	$1.46 -0.4%	$6.67 +355.4%	-23.8%	$163.56M	$10.19M	N/A	163	Positive News
FTH Sensei Biotherapeutics	2.9656 of 5 stars	$26.89 -0.8%	$56.25 +109.2%	N/A	$700.26M	N/A	N/A	29	Short Interest Increase
NVCT Nuvectis Pharma	2.3786 of 5 stars	$20.03 -6.4%	$36.25 +81.0%	+193.2%	$698.26M	N/A	N/A	13
PHAR Pharming Group	4.3284 of 5 stars	$9.68 -1.2%	$38.67 +299.4%	-35.4%	$693.62M	$366.48M	80.67	407	News Coverage
MDXG MiMedx Group	3.2949 of 5 stars	$4.62 +1.5%	$8.57 +85.5%	-28.0%	$663.21M	$418.63M	115.53	808	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IPHA) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Innate Pharma (IPHA) Competitors

IPHA vs. FTH, NVCT, PHAR, MDXG, and DBVT

How does Innate Pharma compare to Sensei Biotherapeutics?

Summary

How does Innate Pharma compare to Nuvectis Pharma?

Summary

How does Innate Pharma compare to Pharming Group?

Summary

How does Innate Pharma compare to MiMedx Group?

Summary

How does Innate Pharma compare to DBV Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPHA vs. The Competition

Innate Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Innate Pharma (IPHA) Competitors

IPHA vs. FTH, NVCT, PHAR, MDXG, and DBVT

How does Innate Pharma compare to Sensei Biotherapeutics?

Which has more volatility & risk, FTH or IPHA?

Does the media refer more to FTH or IPHA?

Do institutionals and insiders have more ownership in FTH or IPHA?

Do analysts prefer FTH or IPHA?

Which has higher valuation & earnings, FTH or IPHA?

Is FTH or IPHA more profitable?

Summary

How does Innate Pharma compare to Nuvectis Pharma?

Does the media prefer NVCT or IPHA?

Which has more volatility & risk, NVCT or IPHA?

Which has better valuation & earnings, NVCT or IPHA?

Is NVCT or IPHA more profitable?

Do analysts rate NVCT or IPHA?

Do institutionals and insiders hold more shares of NVCT or IPHA?

Summary

How does Innate Pharma compare to Pharming Group?

Which has more risk and volatility, PHAR or IPHA?

Does the media favor PHAR or IPHA?

Which has higher valuation & earnings, PHAR or IPHA?

Is PHAR or IPHA more profitable?

Do insiders & institutionals believe in PHAR or IPHA?

Do analysts recommend PHAR or IPHA?

Summary

How does Innate Pharma compare to MiMedx Group?

Does the media favor MDXG or IPHA?

Do insiders and institutionals believe in MDXG or IPHA?

Which has preferable earnings & valuation, MDXG or IPHA?

Which has more volatility and risk, MDXG or IPHA?

Do analysts prefer MDXG or IPHA?

Is MDXG or IPHA more profitable?

Summary

How does Innate Pharma compare to DBV Technologies?

Does the media refer more to IPHA or DBVT?

Do analysts rate IPHA or DBVT?

Do insiders & institutionals believe in IPHA or DBVT?

Which has better valuation and earnings, IPHA or DBVT?

Which has more volatility and risk, IPHA or DBVT?

Is IPHA or DBVT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPHA vs. The Competition

Innate Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools